Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic

J Am Acad Dermatol. 2020 Sep;83(3):e251-e252. doi: 10.1016/j.jaad.2020.06.015. Epub 2020 Jun 10.

Authors

Donovan G Kearns¹, Shelley Uppal², Vipawee S Chat³, Jashin J Wu⁴

Affiliations

¹ Loma Linda University School of Medicine, Loma Linda, California.
² Albany Medical College School of Medicine, Albany, New York.
³ Medical College of Georgia at Augusta University, Augusta, Georgia.
⁴ Dermatology Research and Education Foundation, Irvine, California. Electronic address: jashinwu@gmail.com.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Betacoronavirus / immunology*
COVID-19
Clinical Decision-Making
Coronavirus Infections / epidemiology*
Coronavirus Infections / immunology
Coronavirus Infections / prevention & control
Coronavirus Infections / virology
Dermatitis, Atopic / drug therapy*
Dermatitis, Atopic / immunology
Dermatology / standards
Humans
Interleukin-4 Receptor alpha Subunit / antagonists & inhibitors
Interleukin-4 Receptor alpha Subunit / immunology
Pandemics / prevention & control
Pneumonia, Viral / epidemiology*
Pneumonia, Viral / immunology
Pneumonia, Viral / prevention & control
Pneumonia, Viral / virology
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Risk Assessment
SARS-CoV-2
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
IL4R protein, human
Interleukin-4 Receptor alpha Subunit
dupilumab